https://prabadinews.com/

Immunoglobulin Replacement Therapy Fails to Lower Hospitalizations in CLL, Study Finds

New research reveals that immunoglobulin replacement therapy fails to lower infection-related hospitalizations in those with chronic lymphocytic leukemia (CLL), raising…

FDA Issues CRL to Vatiquinone NDA Indicated For Friedreich Ataxia

The complete response letter (CRL) stated that vatiquinone’s new drug application (NDA) did not provide substantial evidence of efficacy and…

Alaska Law Implements Time Limits for Prior Authorization Decisions on Medication Coverage

The law has support from patients, health care providers, pharmacists, and the largest health insurance provider in the state.

Cardiovascular Screening Rates Declined in Adults With Disabilities During COVID-19 Pandemic

Individuals with cognitive and physical disabilities faced difficulties in health care utilization and had reduced rates of preventive cardiovascular screenings…

FDA Reviews Plozasiran: A Potential First-in-Class Therapy for Familial Chylomicronemia Syndrome

Plozasiran significantly reduces triglyceride levels and pancreatitis risk in FCS patients, offering hope for effective treatment options.

Arbli From Scienture

FDA approves a new liquid formulation of losartan for hypertension treatment, enhancing accessibility for adults and children over 6 years…

Pharmacists and Providers: Key Collaborators in the Shift Toward Decentralized and Virtual Health Care

Virtual health care enhances patient experiences, integrates complex data, and ensures medication access through provider-pharmacist collaboration.

New Drug Combination Shows Promise Against Resistant Influenza Strains

Researchers unveil a promising drug combination, arainosine and theobromine, that effectively targets influenza A M2 channels, outperforming existing treatments.

Semaglutide Receives FDA Approval for Treatment of MASH

FDA approves semaglutide for treating MASH, offering new hope for affected individuals.